Audentes Therapeutics Announces Publication of Data from RECENSUS, a Retrospective Medical Record Review of Patients With X-Linked Myotubular Myopathy

SAN FRANCISCO, Nov. 21, 2017 -- (Healthcare Sales & Marketing Network) -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatenin... Biopharmaceuticals Audentes Therapeutics, X-Linked Myotubular Myopathy, RECENSUS Study
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news